INCREASED RISK OF BLADDER CANCER! Medical regulators in France and Germany have suspended the sales of the Type 2 Diabetes drug Actos (piogliatazone) because of a possible increased risk of bladder cancer. This came following a study commissioned by the French Medicines Agency which reported that people taking Actos were more likely to develop bladder cancer. The study involved approximately155,000 people taking Actos in France from 2006 to 2009 with a control group of 1.3 million other diabetics who were not taking Actos. Researchers reported finding a 22 percent higher risk of bladder cancer among the Actos users.
The FDA announced that it was reviewing Actos for a possible bladder cancer risk in September 2010. According to the agency, data from a 10-year study submitted by Takeda, the maker of Actos, had not indicated a statistically significant association between exposure to the drug and bladder cancer risk. The FDA did note that there was a possible increase in risk for those taking higher dosages or for longer duration.
A review by researchers of Adverse Event reports to the FDA between 2004-2009, has suggested that Actos patients faced a "disproportionate risk” of bladder cancer.
Actos (pioglitazone) is an anti-diabetic drug from the thiazolidinedione class. It is marketed by the Japanese pharmaceutical company, Takeda Pharmaceutical Company and its North American susidiaries. It can be used by itself or in combination with other drugs.
Actos is associated with following side effects:
- Bladder Cancer
- Heart Attack
- Congestive Heart Failure
- Heart Related Death
If you or a loved one have suffered any of the injuries or side effects listed above you may be entitled to financial compensation for you financial loss, pain and suffering. Please fill out the contact form or call (877) 917-5250 to contact us to discuss your rights. The consultation is free.
Lawsuits of Interest
- 1 of 4